Puretech Health (LON:PRTC) Receives Buy Rating from Numis Securities

Puretech Health (LON:PRTC)‘s stock had its “buy” rating reissued by stock analysts at Numis Securities in a report released on Tuesday, February 20th. They presently have a GBX 259 ($3.58) target price on the stock. Numis Securities’ target price would suggest a potential upside of 59.88% from the company’s current price.

PRTC has been the topic of several other reports. Peel Hunt boosted their price objective on Puretech Health from GBX 302 ($4.17) to GBX 313 ($4.32) and gave the company a “buy” rating in a research report on Friday, January 26th. Jefferies Group restated a “buy” rating on shares of Puretech Health in a research report on Friday, November 17th. Liberum Capital reiterated a “buy” rating and issued a GBX 248 ($3.43) target price on shares of Puretech Health in a research report on Friday, January 26th. Finally, N+1 Singer reiterated a “buy” rating on shares of Puretech Health in a research report on Thursday, November 30th. Five equities research analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and an average target price of GBX 260.20 ($3.59).

Shares of Puretech Health (LON:PRTC) traded up GBX 4 ($0.06) during trading on Tuesday, hitting GBX 162 ($2.24). The stock had a trading volume of 50,255 shares, compared to its average volume of 66,914. Puretech Health has a fifty-two week low of GBX 110 ($1.52) and a fifty-two week high of GBX 183.50 ($2.54). The stock has a market capitalization of $383.14 and a P/E ratio of -852.63.

In other news, insider Robert Langer bought 4,300 shares of the firm’s stock in a transaction that occurred on Tuesday, March 13th. The shares were bought at an average cost of GBX 162 ($2.24) per share, for a total transaction of £6,966 ($9,624.21).

COPYRIGHT VIOLATION WARNING: This piece of content was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.thelincolnianonline.com/2018/03/14/numis-securities-reiterates-buy-rating-for-puretech-health-prtc-2.html.

Puretech Health Company Profile

PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets.

Analyst Recommendations for Puretech Health (LON:PRTC)

Receive News & Ratings for Puretech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puretech Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply